News
Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting
Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region
Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region
Celyad Announces October and November 2019 Investor Conference Schedule
Celyad Announces October and November 2019 Investor Conference Schedule
Celyad to Participate in Upcoming September 2019 Conferences
Celyad to Participate in Upcoming September 2019 Conferences
Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call
Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call
Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors
Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors
Celyad to Host Conference Call to Review Clinical Update from ESMO 21st World GI Congress
Celyad to Host Conference Call to Review Clinical Update from ESMO 21st World GI Congress
Celyad Announces Strategic Updates to the Autologous r/r AML and MDS Program
Celyad Announces Strategic Updates to the Autologous r/r AML and MDS Program
Celyad to Participate in Upcoming June 2019 Conferences
Celyad to Participate in Upcoming June 2019 Conferences
Celyad to Present Data at 24th Congress of the European Hematology Association
Celyad to Present Data at 24th Congress of the European Hematology Association
Celyad Announces May 2019 Investor Conference Schedule
Celyad Announces May 2019 Investor Conference Schedule
Celyad Announces April 2019 Investor Conference Schedule
Celyad Announces April 2019 Investor Conference Schedule